Berberine for Stage IV Cancer
Also known as: Berberine HCl, Goldenseal extract
Berberine's AMPK activation and multi-pathway anti-cancer effects mirror metformin's but with additional direct cytotoxic properties.
Mechanism of Action
Berberine activates AMPK, inhibits mTOR signaling, arrests cancer cell cycle (G1 phase), induces apoptosis through mitochondrial pathway, inhibits NF-κB-driven survival signaling, and modulates gut microbiome composition. It also inhibits telomerase and angiogenesis. Multiple independent anti-cancer mechanisms make it attractive for multi-targeted therapy.
General mechanism: Isoquinoline alkaloid. AMPK activator, NF-κB inhibitor, BACE1 inhibitor, gut microbiome modulator, telomerase inhibitor.
Current Evidence
Extensive preclinical evidence. Phase I/II trials ongoing for colorectal cancer (adjunctive with chemotherapy). Gut microbiome modulation may enhance immunotherapy response. Bioavailability is limited by poor oral absorption.
Clinical Status: Phase I/II for colorectal cancer. Available as supplement. Metabolic syndrome/diabetes trials provide safety data.
Safety Profile
GI effects (diarrhea, constipation). Should not be combined with metformin (additive hypoglycemia risk). Contraindicated in pregnancy. Generally well-tolerated.
Key Research Questions
- Can berberine's gut microbiome effects enhance immunotherapy response?
- What formulation improvements can overcome bioavailability limitations?